Trial Profile
A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma Who Are at Risk for Relapse After High Dose Chemotherapy and Autologous Stem Cell Transplant (ASCT)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 19 Jul 2019
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Registrational
- Acronyms PATH
- Sponsors Novartis; Novartis Pharmaceuticals
- 10 Dec 2013 Final results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
- 15 Jul 2013 This trial is recruiting in Belgium, France, United Kingdom and discontinued in Spain, Italy as reported by European Clinical Trials Database record.
- 31 May 2012 Planned End Date changed from 1 Mar 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.